PubMed

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.

Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C.

Diabetes Care. 2008 Sep;31(9):1816-23. Epub 2008 Jun 20.PMID: 18753666 [PubMed - indexed for MEDLINE]Related articlesFree article

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C.

J Clin Endocrinol Metab. 2007 Aug;92(8):2977-83. Epub 2007 May 15.PMID: 17504894 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG.

Diabetes Care. 2002 Apr;25(4):724-30.PMID: 11919132 [PubMed - indexed for MEDLINE]Related articlesFree article

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.

Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG.

Diabetes Technol Ther. 2002;4(1):51-61.PMID: 12017421 [PubMed - indexed for MEDLINE]Related articles

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, Koda JE, Weyer C.

Obesity (Silver Spring). 2009 Sep;17(9):1736-43. Epub 2009 Jun 11.PMID: 19521351 [PubMed - indexed for MEDLINE]Related articles

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.

Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C.

Obes Res. 2004 Apr;12(4):661-8.PMID: 15090634 [PubMed - indexed for MEDLINE]Related articles

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG.

Diabet Med. 2004 Nov;21(11):1204-12.PMID: 15498087 [PubMed - indexed for MEDLINE]Related articles

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.

Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C.

Metabolism. 2003 Dec;52(12):1638-42.PMID: 14669170 [PubMed - indexed for MEDLINE]Related articles

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG.

Diabetes Care. 2003 Mar;26(3):784-90.PMID: 12610038 [PubMed - indexed for MEDLINE]Related articlesFree article

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.

Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O.

Diabetes Care. 2007 Nov;30(11):2794-9. Epub 2007 Aug 13.PMID: 17698615 [PubMed - indexed for MEDLINE]Related articlesFree article

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.

Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, Kolterman O, Weyer C.

Diabetes Obes Metab. 2003 Nov;5(6):408-14.PMID: 14617226 [PubMed - indexed for MEDLINE]Related articles

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.

Smith SR, Blundell JE, Burns C, Ellero C, Schroeder BE, Kesty NC, Chen KS, Halseth AE, Lush CW, Weyer C.

Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E620-7. Epub 2007 May 15.PMID: 17505051 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes.

Wysham C, Lush C, Zhang B, Maier H, Wilhelm K.

Curr Med Res Opin. 2008 Jan;24(1):79-85.PMID: 18031595 [PubMed - indexed for MEDLINE]Related articles

Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.

Singh-Franco D, Robles G, Gazze D.

Clin Ther. 2007 Apr;29(4):535-62. Review.PMID: 17617279 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME.

Clin Ther. 2007 Jan;29(1):139-53.PMID: 17379054 [PubMed - indexed for MEDLINE]Related articles

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.

Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH.

Obes Res. 2003 Jun;11(6):722-33.PMID: 12805393 [PubMed - indexed for MEDLINE]Related articles

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.

Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group.

Int J Obes Relat Metab Disord. 2004 Nov;28(11):1399-410.PMID: 15486569 [PubMed - indexed for MEDLINE]Related articles

Effect of acarbose on weight maintenance after dietary weight loss in obese subjects.

Hauner H, Petzinna D, Sommerauer B, Toplak H.

Diabetes Obes Metab. 2001 Dec;3(6):423-7.PMID: 11903414 [PubMed - indexed for MEDLINE]Related articles

Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study.

Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP.

JAMA. 2003 Apr 9;289(14):1826-32.PMID: 12684362 [PubMed - indexed for MEDLINE]Related articlesFree article

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.

Finer N, James WP, Kopelman PG, Lean ME, Williams G.

Int J Obes Relat Metab Disord. 2000 Mar;24(3):306-13.PMID: 10757623 [PubMed - indexed for MEDLINE]Related articles